Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Sieber M, et al. Among authors: hansmann ml. Ann Oncol. 2004 Feb;15(2):276-82. doi: 10.1093/annonc/mdh046. Ann Oncol. 2004. PMID: 14760122 Free article. Clinical Trial.
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A. Josting A, et al. Among authors: hansmann ml. J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25. J Clin Oncol. 2010. PMID: 20975066 Clinical Trial.
Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H. Diehl V, et al. Among authors: hansmann ml. J Clin Oncol. 1999 Mar;17(3):776-83. doi: 10.1200/JCO.1999.17.3.776. J Clin Oncol. 1999. PMID: 10071266 Clinical Trial.
Monocytoid B-cells occurring in Hodgkin's disease.
Plank L, Hansmann ML, Fischer R. Plank L, et al. Among authors: hansmann ml. Virchows Arch. 1994;424(3):321-6. doi: 10.1007/BF00194618. Virchows Arch. 1994. PMID: 8186898
Classical Hodgkin's disease. Clinical impact of the immunophenotype.
von Wasielewski R, Mengel M, Fischer R, Hansmann ML, Hübner K, Franklin J, Tesch H, Paulus U, Werner M, Diehl V, Georgii A. von Wasielewski R, et al. Among authors: hansmann ml. Am J Pathol. 1997 Oct;151(4):1123-30. Am J Pathol. 1997. PMID: 9327746 Free PMC article.
492 results